Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
|Videos|August 30, 2016
A 200-Mile Run for Multiple Myeloma
Author(s)Eric Gelber
For years, Eric Gelber has been embarking on long distance runs to raise money for the Multiple Myeloma Research Foundation. This September, he will attempt his longest run yet: 200 miles through Central Park over the course of a weekend
Advertisement
For years, Eric Gelber has been embarking on long distance runs to raise money for the Multiple Myeloma Research Foundation. This September, he will attempt his longest run yet: 200 miles through Central Park over the course of a weekend.
Advertisement
Related to this article
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.
Psychiatrist Dr. Yesne Alici of Memorial Sloan Kettering Cancer Center answers questions about family relationships during cancer, from asking for help to talking with children and friends.
After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
3 Quality-of-Life Results From ESMO 2026 Patients Should Know
3
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
4
What New KRAS Drug Data From ESMO 2026 Mean for Patients
5